Appili Therapeutics Stock Net Income
| APLIF Stock | USD 0.02 0 16.43% |
As of the 4th of February, Appili Therapeutics shows the Mean Deviation of 5.46, risk adjusted performance of 0.0258, and Downside Deviation of 14.14. Appili Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Appili Therapeutics information ratio and the relationship between the maximum drawdown and skewness to decide if Appili Therapeutics is priced correctly, providing market reflects its regular price of 0.0163 per share. As Appili Therapeutics appears to be a penny stock we also recommend to validate its total risk alpha numbers.
Appili Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Appili Therapeutics' valuation are provided below:Appili Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Appili |
Appili Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Appili Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Appili Therapeutics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Appili Therapeutics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Appili Therapeutics or generate 0.0% return on investment in Appili Therapeutics over 90 days. Appili Therapeutics is related to or competes with Ayala Pharmaceuticals. Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for... More
Appili Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Appili Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Appili Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 14.14 | |||
| Information Ratio | 0.017 | |||
| Maximum Drawdown | 42.48 | |||
| Value At Risk | (16.67) | |||
| Potential Upside | 20.0 |
Appili Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Appili Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Appili Therapeutics' standard deviation. In reality, there are many statistical measures that can use Appili Therapeutics historical prices to predict the future Appili Therapeutics' volatility.| Risk Adjusted Performance | 0.0258 | |||
| Jensen Alpha | 0.1986 | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | 0.0115 | |||
| Treynor Ratio | 1.21 |
Appili Therapeutics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0258 | |||
| Market Risk Adjusted Performance | 1.22 | |||
| Mean Deviation | 5.46 | |||
| Semi Deviation | 6.99 | |||
| Downside Deviation | 14.14 | |||
| Coefficient Of Variation | 4427.1 | |||
| Standard Deviation | 9.56 | |||
| Variance | 91.36 | |||
| Information Ratio | 0.017 | |||
| Jensen Alpha | 0.1986 | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | 0.0115 | |||
| Treynor Ratio | 1.21 | |||
| Maximum Drawdown | 42.48 | |||
| Value At Risk | (16.67) | |||
| Potential Upside | 20.0 | |||
| Downside Variance | 200.06 | |||
| Semi Variance | 48.85 | |||
| Expected Short fall | (15.24) | |||
| Skewness | 0.3011 | |||
| Kurtosis | 1.36 |
Appili Therapeutics Backtested Returns
Appili Therapeutics appears to be out of control, given 3 months investment horizon. Appili Therapeutics secures Sharpe Ratio (or Efficiency) of 0.071, which signifies that the company had a 0.071 % return per unit of risk over the last 3 months. By analyzing Appili Therapeutics' technical indicators, you can evaluate if the expected return of 0.63% is justified by implied risk. Please makes use of Appili Therapeutics' Downside Deviation of 14.14, mean deviation of 5.46, and Risk Adjusted Performance of 0.0258 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Appili Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Appili Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Appili Therapeutics is expected to be smaller as well. Please check Appili Therapeutics' downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether Appili Therapeutics' price patterns will revert.
Auto-correlation | -0.37 |
Poor reverse predictability
Appili Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Appili Therapeutics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Appili Therapeutics price movement. The serial correlation of -0.37 indicates that just about 37.0% of current Appili Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.37 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Appili Therapeutics reported net income of (25.12 Million). This is 107.36% lower than that of the Healthcare sector and 135.86% lower than that of the Biotechnology industry. The net income for all United States stocks is 104.4% higher than that of the company.
Appili Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Appili Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Appili Therapeutics could also be used in its relative valuation, which is a method of valuing Appili Therapeutics by comparing valuation metrics of similar companies.Appili Therapeutics is currently under evaluation in net income category among its peers.
Appili Fundamentals
| Return On Equity | -9.39 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (6.41) % | |||
| Current Valuation | 6.66 M | |||
| Shares Outstanding | 121.27 M | |||
| Shares Owned By Insiders | 12.43 % | |||
| Shares Owned By Institutions | 12.03 % | |||
| Price To Book | 1.48 X | |||
| Price To Sales | 3.98 X | |||
| Revenue | 1.39 M | |||
| Gross Profit | 1.39 M | |||
| EBITDA | (23.51 M) | |||
| Net Income | (25.12 M) | |||
| Cash And Equivalents | 5.55 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 4.88 M | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (19.08 M) | |||
| Earnings Per Share | (0.32) X | |||
| Target Price | 0.23 | |||
| Beta | 1.01 | |||
| Market Capitalization | 5.08 M | |||
| Total Asset | 8.28 M | |||
| Z Score | -6.0 | |||
| Net Asset | 8.28 M |
About Appili Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Appili Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Appili Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Appili Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Appili Pink Sheet
Appili Therapeutics financial ratios help investors to determine whether Appili Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.